Shanwaishan released its 2026 half-year report, with first-half net profit attributable to the parent of 94.37 million yuan, up 71.5% year-on-year. Operating revenue was 464 million yuan, up 29.8% year-on-year; net profit attributable to the parent after deducting non-recurring items was 84.98 million yuan, up 67.6% year-on-year; net operating cash flow was 41 million yuan, down 40.1% year-on-year; earnings per share were 0.2968 yuan. In the second quarter, operating revenue was 234 million yuan, up 39.4% year-on-year; net profit attributable to the parent was 39.89 million yuan, up 121.2% year-on-year. As of the end of the second quarter, total assets were 2.448 billion yuan, up 4.3% from the end of the previous year; net assets attributable to the parent were 1.811 billion yuan, up 1.8% from the end of the previous year. During the reporting period, sales revenue from the company's self-produced blood purification consumables rose significantly, driving overall revenue growth. Research and development investment reached 41.03 million yuan, accounting for 8.85% of operating revenue.
SWS Hemodialysis Care Co. Ltd. AFirst-half net profit up 71.5% year-on-year, with strong revenue growth.
